The biosafety of drug candidates or any other xenobiotic or product used by humans is a fundamental issue that requires the application of guidelines and the implementation of standardized experimental tests.

Bertin Pharma, throughout its years of expertise, has always focused on the efficacy as much as on the safety of products assessed in its laboratories.

Safety Pharmacology including Safety ImmunoPharmacology & the Viral & Prions risk are historical topics for Bertin Pharma biologics (peptides/proteins, gene therapy, cell therapy, etc.) and/or blood derivative products but remain essential subjects and two of its core activities.

Now, impurities and Host Cell Contaminants such as proteins (HCP) and nucleic acids are important issues, also evaluated by Bertin Pharma.